Article

Ellex announces rebranding; introduces retina laser

Ellex Medical Laser Ltd., of Adelaide, Australia, announces it will establish Ellex as its worldwide brand name - consistent with its name on the Australian Stock Exchange. Ellex replaces the brand name Laserex on all products, and the company's U.S. and Japanese subsidiaries will also adopt the name.

Ellex Medical Laser Ltd., of Adelaide, Australia, announces it will establish Ellex as its worldwide brand name - consistent with its name on the Australian Stock Exchange. Ellex replaces the brand name Laserex on all products, and the company's U.S. and Japanese subsidiaries will also adopt the name.

In addition, Ellex is relocating its global headquarters responsible for global sales, marketing, and customer service to the San Francisco Bay area in the second half of 2006. The move is part of the company's strategy to be centrally located to its three main markets in North America, North Asia, and Europe. The headquarters will be under the direction of Ellex Chief Executive Officer Peter Falzon.

The company's manufacturing, engineering, and finance operations will remain in Adelaide.

In other news, Ellex introduces the Integre Duo solid-state red and green photocoaguator at the American Society of Cataract and Refractive Surgery meeting. Pending FDA clearance, the company expects the system to be commercially available in the United States in July.

The photocoagulator provides choice and versatility to ophthalmologists who treat challenging retinal conditions, according to the company.

"We have followed our customers' desire to integrate the clinical utility and performance of the existing ion argon-krypton lasers and not compromise those benefits when choosing a solid-state laser today," Falzon said. "The Integre Duo provides the benefits of both simultaneous true red and green wavelength selection in a compact solid-state design."

For more information, visit Ellex at Booth 2526.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.